|Bid||4.750 x 900|
|Ask||4.800 x 1800|
|Day's Range||4.725 - 4.950|
|52 Week Range||4.050 - 18.350|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.25|
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced its participation at two upcoming healthcare conferences in September. Susan M. Molineaux, Ph.D., the company’s Founder, President and Chief Executive Officer, will present in Boston on Thursday, September 6, at 8:00 a.m. Eastern Time. Calithera is a clinical-stage biopharmaceutical company focused on fighting cancer by discovering, developing, and commercializing novel small molecule drugs that target tumor and immune cell metabolism. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie ...
Calithera (CALA) delivered earnings and revenue surprises of 72.73% and 230.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 9 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
-Two Novel Programs Entering Clinical Development. -Calithera to Host Conference Call Today at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time. SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018-- Calithera Biosciences, ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Calithera Biosciences, Inc. (NASDAQ: CALA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 5:00 PM Eastern ...
Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s second quarter 2018 financial results will be released on Tuesday, August 7, 2018. Company management will host a conference call on Tuesday, August 7, 2018 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.
Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (CALA), Cara Therapeutics Inc. (CARA), Celgene Corp. (CELG), and Celldex Therapeutics Inc. (CLDX). Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares.
Calithera Biosciences Inc’s (NASDAQ:CALA): Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets forRead More...
On a per-share basis, the South San Francisco, California-based company said it had a loss of 37 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Calithera Biosciences, Inc. (NASDAQ: CALA) ("Calithera"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CALA as the Company's latest news hit the wire. On April 18, 2018, the San Francisco-based biopharmaceutical Company announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead product candidate, CB-839, in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who have received one or two prior lines of therapy, including at least one vascular endothelial growth factor tyrosine kinase inhibitor or the combination of nivolumab and ipilimumab.
Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.